During the last session, Mersana Therapeutics Inc (NASDAQ:MRSN)’s traded shares were 1.95 million, with the beta value of the company hitting 1.53. At the end of the trading day, the stock’s price was $1.97, reflecting an intraday loss of -8.37% or -$0.18. The 52-week high for the MRSN share is $6.28, that puts it down -218.78 from that peak though still a striking 59.39% gain since the share price plummeted to a 52-week low of $0.80. The company’s market capitalization is $241.05M, and the average intraday trading volume over the past 10 days was 1.03 million shares, and the average trade volume was 1.59 million shares over the past three months.
Mersana Therapeutics Inc (MRSN) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.44. MRSN has a Sell rating from 0 analyst(s) out of 5 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 5 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.17.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Mersana Therapeutics Inc (NASDAQ:MRSN) trade information
Mersana Therapeutics Inc (MRSN) registered a -8.37% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -8.37% in intraday trading to $1.97, hitting a weekly high. The stock’s 5-day price performance is -5.29%, and it has moved by -3.43% in 30 days. Based on these gigs, the overall price performance for the year is -47.61%. The short interest in Mersana Therapeutics Inc (NASDAQ:MRSN) is 9.68 million shares and it means that shorts have 5.79 day(s) to cover.
Mersana Therapeutics Inc (MRSN) estimates and forecasts
Statistics show that Mersana Therapeutics Inc has outperformed its competitors in share price, compared to the industry in which it operates. Mersana Therapeutics Inc (MRSN) shares have gone down -24.95% during the last six months, with a year-to-date growth rate more than the industry average at 59.46% against 15.20. In the rating firms’ projections, revenue will increase 7.70% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 9.13M as predicted by 9 analyst(s). Meanwhile, a consensus of 9 analyst(s) estimates revenue growth to 10.15M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 10.65M and 7.7M respectively. In this case, analysts expect current quarter sales to shrink by -14.30% and then jump by 31.90% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 11.93%. While earnings are projected to return 58.18% in 2024.
MRSN Dividends
Mersana Therapeutics Inc is due to release its next quarterly earnings in August. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Mersana Therapeutics Inc (NASDAQ:MRSN)’s Major holders
The next largest institutional holding, with 11.33 million shares, is of VR ADVISER, LLC’s that is approximately 9.3919% of outstanding shares. At the market price on 2024-03-31, these shares were valued at $50.75 million.
